G protein-coupled receptor

Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences

Retrieved on: 
Monday, April 8, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, G protein-coupled receptor, Multimedia, Gq alpha subunit, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240408769768/en/
    Anthony Johnson & Sean A. MacDonald (Photo: Domain Therapeutics)
    Location: Metro Toronto Convention Centre (North Building), Toronto, Canada

GPCR Therapeutics Announces Publication in PNAS Using Cutting Edge Spectroscopy to Detect GPCR Heteromers on Live Cancer Cells

Retrieved on: 
Monday, April 1, 2024
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Data Management, Science, Oncology, Texas Tech University, GPCR, Associate, CXCR4, Adrenaline, PNAS, National academy, G protein-coupled receptor, Drug, Therapy, Pharmaceutical industry

This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics.

Key Points: 
  • This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics.
  • Detection of multimeric complexes by CXCR4 with other GPCRs in a live-cell environment validates the dual GPCR targeting hypothesis.
  • The work uses time-resolved fluorescence spectroscopy to quantify CXCR4 and β2AR interactions as they form complexes in live cells under physiological conditions.
  • Dr. Dong Seung Seen, Founder and CEO of GPCR Therapeutics based in Seoul, spoke about Dr. Caculitan’s accomplishments.

Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases

Retrieved on: 
Thursday, March 28, 2024
Technology, Research, Other Technology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, GPCR, Obesity, Drug discovery, G protein-coupled receptor, Therapy, CSO, VHH, DSM-IV codes, Pharmaceutical industry

Confo Therapeutics , a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO).

Key Points: 
  • Confo Therapeutics , a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
  • The 2-year grant will be used to expand Confo’s ongoing R&D efforts in the discovery of next-generation medicines targeting Class B GPCRs using its patent-protected technology platform.
  • Class B GPCRs are recognized as important targets for new medicines, particularly in chronic endocrine and metabolic diseases.
  • Cedric Ververken, CEO of Confo Therapeutics, commented: “Receiving this additional VLAIO grant will strengthen our existing small molecule and antibody discovery efforts on high-value Class B GPCRs, which further paves the way to unlock new treatments for a range of endocrine and metabolic indications including obesity.

Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GPCR, Gene, Immunotherapy, Patient, Immunosuppression, PAR2, ICB, Research, Tumor microenvironment, Cancer, G protein-coupled receptor, IND, AACR, Gq alpha subunit, Therapy, Drug resistance, Module (mathematics)

PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.

Key Points: 
  • PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.
  • Its upregulation across a variety of cancer types and expression on diverse cells within the tumor microenvironment underscore PAR2’s critical role in cancer development.
  • Remarkably, when compared to its most advanced competitors positioned in other therapeutic areas, this candidate has demonstrated clear differentiated features.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, commented: “We are excited to present our newest findings on DT-9045 at AACR.

Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

Retrieved on: 
Thursday, March 14, 2024
Eurosport 1, Drug discovery, Business, EPO, G protein-coupled receptor, IP, European Patent Convention, Patent, Therapy, Pharmaceutical industry

STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'. This patent covers processes related to the Salipro® platform and represents a pivotal milestone that strengthens Salipro Biotech's position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Key Points: 
  • This additional European patent will further strengthen Salipro Biotech's integrated IP portfolio protecting its proprietary Salipro® platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.
  • STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'.
  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech's unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

Retrieved on: 
Thursday, March 14, 2024
Eurosport 1, Drug discovery, Business, EPO, G protein-coupled receptor, IP, European Patent Convention, Patent, Therapy, Pharmaceutical industry

STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'. This patent covers processes related to the Salipro® platform and represents a pivotal milestone that strengthens Salipro Biotech's position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Key Points: 
  • This additional European patent will further strengthen Salipro Biotech's integrated IP portfolio protecting its proprietary Salipro® platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.
  • STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'.
  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech's unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Retrieved on: 
Tuesday, March 12, 2024
GPCR, CLD, CDMO, Organization, Partnership, Patient, CGMP, Research, Cutaneous T-cell lymphoma, Cancer, G protein-coupled receptor, CTCL, Gq alpha subunit, Therapy, CCR8, Vaccine

Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.

Key Points: 
  • Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.
  • Chime Biologics' first global modular facility with single-use bioprocessing technology meets international cGMP standards with proven audit track records.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: "We're thrilled to collaborate with Chime Biologics, a great scientific and manufacturing expert, to advance DT-7012, our leading anti-CCR8 candidate, to the next development stage.
  • At Domain, we prioritize precision research and innovation and embrace new partnerships with organizations that share our vision and passion to advance immuno-oncology".

Orion Biotechnology Presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston

Retrieved on: 
Thursday, March 7, 2024
Therapy, Orion, Drug discovery, GIPR, GPCR, G protein-coupled receptor, CXCR6

Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.

Key Points: 
  • Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.
  • Dr. Oliver Hartley, Orion’s Vice President of Drug Discovery, will be presenting Orion’s PROcisionXTM discovery platform and its ability to unlock peptide and protein GPCRs with industry leading efficiency.
  • Additionally, Dr. Hartley will provide an update on Orion’s portfolio of GPCR-targeted therapeutics, including the recent discovery of both antagonists and agonists against GIPR and CXCR6.
  • Commenting on his presentation, Dr. Hartley said “I’m pleased to be presenting Orion’s technology and its ability to rapidly generate innovative therapies for metabolic and immunological diseases.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Retrieved on: 
Wednesday, February 21, 2024
Immunization, G protein-coupled receptor, Drug discovery, ADC, Antibody, Eurosport 1, Protein, Cancer, Vaccine

ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Key Points: 
  • ActivMAb’s new “Antigen Virus” application is a powerful complement to drug discovery strategies targeting complex protein targets including ion channels and G-protein coupled receptors (GPCRs) such as chemokine receptors.
  • We believe that this is a much more highly purified presentation and efficient selection technology than the complex natural membrane fragments that have been termed virus-like particles.
  • “We have recently publicized success in selecting high value antibodies against challenging multi-pass membrane targets.
  • We are excited to be able to capitalize on what we believe is recognition of the unique capabilities of our drug discovery technology.

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Tuesday, February 20, 2024
Lilium, Therapy, Research, Doctor of Philosophy, Drug resistance, Chemical biology, G protein-coupled receptor, Biology, Obesity, Pain, MIT, Harvard University, Drug discovery, Eurosport 1, Health, Fujifilm, Faculty (division), Disease, Massachusetts General Hospital, Harvard Medical School, Infection, Publication, Faculty, Fujifilm Diosynth Biotechnologies, Management

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.